NASDAQ:PETX - Aratana Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.90 +0.09 (+2.36 %) (As of 03/19/2019 04:00 PM ET)Previous Close$3.81Today's Range$3.76 - $3.9452-Week Range$3.30 - $7.16Volume372,441 shsAverage Volume690,412 shsMarket Capitalization$191.00 millionP/E Ratio-12.22Dividend YieldN/ABeta1.38 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs. Its licensed products include canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States; AT-003, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats and dogs; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-017, a listeria based antigen delivery system for treating canine lymphoma in dogs; AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications; and AT-008, a therapeutic candidate for treating canine lymphoma in dogs in Europe. In addition, the company develops other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas. Receive PETX News and Ratings via Email Sign-up to receive the latest news and ratings for PETX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PETX Previous Symbol CUSIPN/A CIK1509190 Webwww.aratana.com Phone913-353-1000Debt Debt-to-Equity RatioN/A Current Ratio10.46 Quick Ratio8.40Price-To-Earnings Trailing P/E Ratio-12.22 Forward P/E Ratio-13.45 P/E GrowthN/A Sales & Book Value Annual Sales$35.41 million Price / Sales5.39 Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book1.88Profitability EPS (Most Recent Fiscal Year)($0.32) Net Income$-14,720,000.00 Net Margins-41.57% Return on Equity-14.78% Return on Assets-11.57%Miscellaneous Employees84 Outstanding Shares48,974,000Market Cap$191.00 million Next Earnings Date5/2/2019 (Estimated) OptionableOptionable Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions What is Aratana Therapeutics' stock symbol? Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX." How were Aratana Therapeutics' earnings last quarter? Aratana Therapeutics Inc (NASDAQ:PETX) announced its earnings results on Tuesday, March, 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.06. The biopharmaceutical company had revenue of $4.91 million for the quarter, compared to the consensus estimate of $6.53 million. Aratana Therapeutics had a negative return on equity of 14.78% and a negative net margin of 41.57%. View Aratana Therapeutics' Earnings History. When is Aratana Therapeutics' next earnings date? Aratana Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Aratana Therapeutics. What price target have analysts set for PETX? 3 brokerages have issued 1-year price objectives for Aratana Therapeutics' stock. Their forecasts range from $4.14 to $10.00. On average, they anticipate Aratana Therapeutics' stock price to reach $6.38 in the next twelve months. This suggests a possible upside of 63.6% from the stock's current price. View Analyst Price Targets for Aratana Therapeutics. What is the consensus analysts' recommendation for Aratana Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aratana Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aratana Therapeutics. Has Aratana Therapeutics been receiving favorable news coverage? Media stories about PETX stock have been trending neutral recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aratana Therapeutics earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near future. Who are some of Aratana Therapeutics' key competitors? Some companies that are related to Aratana Therapeutics include ANI Pharmaceuticals (ANIP), Cara Therapeutics (CARA), Eidos Therapeutics (EIDX), Rocket Pharmaceuticals (RCKT), Intra-Cellular Therapies (ITCI), Revance Therapeutics (RVNC), Eagle Pharmaceuticals (EGRX), Vectura Group (VEGPF), Evolus (EOLS), TG Therapeutics (TGTX), ZIOPHARM Oncology (ZIOP), Synthorx (THOR), Crinetics Pharmaceuticals (CRNX), Obseva (OBSV) and Kura Oncology (KURA). What other stocks do shareholders of Aratana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aratana Therapeutics investors own include Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Pieris Pharmaceuticals (PIRS), Progenics Pharmaceuticals (PGNX), Gilead Sciences (GILD), Verastem (VSTM), ACADIA Pharmaceuticals (ACAD), Micron Technology (MU), Adamis Pharmaceuticals (ADMP) and Dynavax Technologies (DVAX). Who are Aratana Therapeutics' key executives? Aratana Therapeutics' management team includes the folowing people: Mr. Craig A. Tooman, Pres, CEO & Board Director (Age 53)Dr. Ernst Heinen, Chief Devel. Officer (Age 56)Mr. Brent A. Standridge, Consultant (Age 61)Ms. Rhonda Hellums, CFO & TreasurerMr. John C. Ayres, VP of Corp. Devel. and Admin., Gen. Counsel & Sec. Who are Aratana Therapeutics' major shareholders? Aratana Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.46%), Engaged Capital LLC (7.17%), General American Investors Co. Inc. (3.29%), Massachusetts Financial Services Co. MA (3.08%), Dimensional Fund Advisors LP (2.54%) and Dimensional Fund Advisors LP (2.54%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin, John C Ayres and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics. Which institutional investors are selling Aratana Therapeutics stock? PETX stock was sold by a variety of institutional investors in the last quarter, including Engaged Capital LLC, General American Investors Co. Inc., NJ State Employees Deferred Compensation Plan, MetLife Investment Advisors LLC, Principal Financial Group Inc., Weiss Multi Strategy Advisers LLC and Stifel Financial Corp. Company insiders that have sold Aratana Therapeutics company stock in the last year include Brent Standridge, Ernst Heinen, John C Ayres and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics. Which institutional investors are buying Aratana Therapeutics stock? PETX stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Assenagon Asset Management S.A., BlackRock Inc., State Board of Administration of Florida Retirement System, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Geode Capital Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Aratana Therapeutics. How do I buy shares of Aratana Therapeutics? Shares of PETX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aratana Therapeutics' stock price today? One share of PETX stock can currently be purchased for approximately $3.90. How big of a company is Aratana Therapeutics? Aratana Therapeutics has a market capitalization of $191.00 million and generates $35.41 million in revenue each year. The biopharmaceutical company earns $-14,720,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Aratana Therapeutics employs 84 workers across the globe. What is Aratana Therapeutics' official website? The official website for Aratana Therapeutics is http://www.aratana.com. How can I contact Aratana Therapeutics? Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected] MarketBeat Community Rating for Aratana Therapeutics (NASDAQ PETX)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 363 (Vote Outperform)Underperform Votes: 231 (Vote Underperform)Total Votes: 594MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe PETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: What is Put Option Volume?